Rezolute Q4 net loss narrows as R&D expenses fall
Rezolute Q4 net loss narrows as R&D expenses fall
Overview
U.S. rare disease drugmaker's fiscal Q4 net loss narrowed from prior year
R&D expenses for fiscal Q4 declined, mainly due to lower manufacturing costs for ersodetug
General and administrative expenses rose, driven by higher stock-based compensation and professional fees
Outlook
Rezolute expects topline results from the upLIFT Phase 3 tumor HI study before end-2026
Company awaits FDA feedback on the sunRIZE study for congenital HI
Result Drivers
LOWER MANUFACTURING COSTS - Co said decrease in R&D expenses was primarily due to lower manufacturing costs for ersodetug
HIGHER STOCK COMPENSATION AND FEES - Co attributed rise in G&A expenses to increased employee-related stock-based compensation and professional fees for future ersodetug commercial activities
Company press release: ID:nGNX3m1Y8y
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Loss Per Share |
| $0.20 |
|
Q4 Net Loss |
| $20.49 mln |
|
Q4 Income From Operations |
| -$21.56 mln |
|
Q4 Operating Expenses |
| $21.56 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Rezolute, Inc. is $6.00, about 50% above its September 23 closing price of $4.00
Reuters Recommended Reads
Sept 22 - Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Sept 24 - Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study
Sept 24 - Merck's drug for diabetes-related eye disease meets trial goal
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)